{
  "docId": "019de070-c58c-706c-98f1-9eec26811648",
  "docSlug": "2a1e5b2d3a1cb25fe50abb3e75ae9bdf",
  "documentTitle": "Alkermes | Investor Day Presentation Deck | 144 slides",
  "authorId": "alkermes",
  "authorName": "Alkermes",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2021-03-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 56,
  "pageCount": 132,
  "prevPage": 55,
  "nextPage": 57,
  "slideType": "agenda",
  "function": "front_matter",
  "density": "balanced",
  "nDataPoints": 0,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de070-c58c-706c-98f1-9eec26811648/56",
  "deckHref": "/decks/019de070-c58c-706c-98f1-9eec26811648",
  "deckJsonHref": "/decks/019de070-c58c-706c-98f1-9eec26811648.json",
  "deckAnchorHref": "/decks/019de070-c58c-706c-98f1-9eec26811648#slide-56",
  "components": [
    {
      "bbox": {
        "h": 0.55,
        "w": 0.85,
        "x": 0.055,
        "y": 0.26
      },
      "kind": "list",
      "text": "1. Harnessing the potential of the IL-2 pathway\n2. Advancing a differentiated IL-2\n   - Nemvaleukin alfa (nemvaleukin) molecular design\n   - Nemvaleukin clinical development strategy\n3. Clinical data overview\n   - ARTISTRY-1 (intravenous dosing): Focus on melanoma and platinum-resistant ovarian cancer\n   - ARTISTRY-2 (subcutaneous dosing): Subcutaneous recommended phase 2 dose and preliminary objective response\n4. Upcoming data and next steps",
      "attrs": null,
      "subkind": "numbered",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ca9aab3f-f7ce-4c43-b355-a7fdc18a0949",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.275,
        "x": 0.055,
        "y": 0.125
      },
      "kind": "title",
      "text": "Today's Agenda",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f9b96b15-e38f-4949-a34b-ecc7f1b04bd2",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [
    {
      "to": 69,
      "from": 55,
      "name": "Quick Win Big Bet",
      "slug": "47-quick-win-big-bet",
      "bestFor": "Transformation planning, 100-day plans, resource allocation",
      "matchId": "59dd9c04-c6d4-46f5-9a3a-eaa6b3829180",
      "evidence": "Slides 55-69 detail the development and potential of Nemvaleukin alfa.",
      "position": 1,
      "objective": "To present Nemvaleukin alfa as a potential game-changer in cancer treatment",
      "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap",
      "confidence": 0.8,
      "description": "Separate initiatives into immediate wins and longer-term strategic bets"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}